Sector: Materials
Director information for INTERNATIONAL FLAVORS & FRAGRANCES (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Brett Icahn | Investor and Portfolio Manager; Director | 46 | ["Mergers & Acquisitions / Integrations","Other Public Board Experience","Investor and portfolio manager at Icahn Capital","Managing the investment strategy for Icahn Capital since October 2020","Board member at SandRidge Energy, Inc. since 2020","Board member at CVR Energy since 2025","Director at multiple companies including Icahn Enterprises LP, Bausch Health Companies Inc., Bausch + Lomb Corporation, and Dana Inc.","Bachelor of Arts from Princeton University","Sharp investment acumen and deep understanding of corporate strategy"] | ["Audit"] | 2026 |
| Cynthia T. Jamison | Former Chief Financial Officer; Director; Chair | 66 | ["Current or Prior CEO","Consumer Products","Mergers & Acquisitions / Integrations","Sustainability / Environmental","Finance / Accounting","ERM / Risk Management","International / Emerging Markets","Other Public Board Experience","Turnaround Chief Financial Officer","Executive/Financial leadership roles at several companies","Chair of the Board of Darden Restaurants","Former board Chair of Tractor Supply Company","Certified public accountant","Member of the Financial Accounting Standards Advisory Council"] | ["Audit","Governance & Corporate Responsibility","Nominations & Governance","Human Capital & Compensation"] | 2026 |
| Dawn C. Willoughby | Former Executive Vice President and Chief Operating Officer; Director; Chair | 56 | ["Executive Vice President and Chief Operating Officer of The Clorox Company","Senior Vice President and General Manager, Clorox Cleaning Division","Vice President and General Manager, Home Care Products","Vice President and General Manager, Glad Products","Experience at The Procter & Gamble Company in sales management","Director of J.M. Smucker Company since 2017","Director of TE Connectivity since March 2020","Bachelor’s degree in Sports Management from the University of Minnesota","Master’s degree in Business Administration from UCLA Anderson School of Business"] | ["Human Capital & Compensation","Innovation","Governance & Corporate Responsibility"] | 2026 |
| J. Erik Fyrwald | Chief Executive Officer; Director; CEO | 66 | ["Current or Prior CEO","Operations / Manufacturing","Consumer Products","Mergers & Acquisitions / Integrations","Human Capital","Sustainability / Environmental","Finance / Accounting","ERM / Risk Management","International / Emerging Markets","Other Public Board Experience","Over four decades of executive and operational experience","Driving innovation and profitable, sustainable growth at leading corporations in the nutrition, agriculture and chemicals industries"] | ["Innovation"] | 2026 |
| Jesus B. Mantas | Retired Senior Executive; Director | 57 | ["Current or Prior CEO","Operations / Manufacturing","Mergers & Acquisitions / Integrations","Human Capital","Sustainability / Environmental","Finance / Accounting","ERM / Risk Management","International / Emerging Markets","Other Public Board Experience","senior technology and management consulting executive","broad corporate governance experience","led the $10B Business Transformation Services unit of IBM Consulting","led Strategy, Innovation, M&A and other IBM divisions","Partner in the High Technology practice of PricewaterhouseCoopers Consulting","served in the Air Force of Spain","currently serves on the boards of Biogen Inc.","serves in the advisory council of NASDAQ Center for Board Excellence","trustee of the J. Patrick McGovern Foundation","holds degrees in Telecommunications and Business Administration","adjunct professor at the University of California Irvine","completed Harvard Business School Corporate Governance"] | ["Audit","Human Capital & Compensation","Governance & Corporate Responsibility"] | 2026 |
| John F. Ferraro | Chair | [] | [] | 2026 | |
| Kathryn J. Boor | [] | ["Audit","Human Capital & Compensation"] | 2026 | ||
| Kevin O’Byrne | Former Chief Financial Officer and Director; Chair of the Board | 61 | ["Current or Prior CEO","Operations / Manufacturing","Mergers & Acquisitions / Integrations","Human Capital","Sustainability / Environmental","Finance / Accounting","ERM / Risk Management","International / Emerging Markets","Other Public Board Experience","Chief Financial Officer and Director of J Sainsbury plc","Chief Executive Officer of Poundland Group Plc","Divisional CEO UK, China and Turkey at Kingfisher Plc","Chief Executive Officer of B&Q UK & Ireland","Group Finance Director of Dixons Retail plc","European Finance Director of Quaker Oats","Chair of the Board of Centrica plc","Senior Independent Director and Chair of the Audit and Risk Committee at Centrica plc","Senior Independent Director and Chair of the Audit Committee of Land Securities Group plc","Bachelor of Arts degree in Business Studies from Trinity College, Dublin","Fellow of the Institute of Chartered Accountants in England & Wales since 1990","Skilled Chief Financial Officer and public company board director with extensive international business and finance experience"] | ["Governance & Corporate Responsibility","Audit"] | 2026 |
| Mark J. Costa | [] | ["Audit","Human Capital & Compensation"] | 2026 | ||
| Mehmood Khan | Chief Executive Officer; Director; Chair | 67 | ["Current or Prior CEO","Consumer Products","Mergers & Acquisitions / Integrations","Sustainability / Environmental","Finance / Accounting","ERM / Risk Management","International / Emerging Markets","Other Public Board Experience","CEO of Hevolution Foundation","Executive Chair of Life Biosciences","Former CEO of Life Biosciences (2019-2024)","Former Vice Chairman and Chief Scientific Officer of Global Research and Development at PepsiCo","Former President of Takeda Global Research & Development Center","Former faculty member at Mayo Clinic and Mayo Medical School","Director of the Diabetes, Endocrine and Nutritional Trials Unit","Leader of programs in diabetes, endocrinology, metabolism and nutrition at Hennepin County Medical Center","Director of Reckitt Benckiser (2018-2025)","Director of CorMedix Inc. (2017-2020)","Medical degree from University of Liverpool","Fellow of the Royal College of Physicians, London","Fellow of the American College of Endocrinology","Elected Fellow in the Department of Pharmacology at University of Oxford","Holds two Honorary PhDs in Humanities and International Law"] | ["Innovation","Human Capital & Compensation"] | 2026 |
| Paul J. Fribourg | Chairman and Chief Executive Officer; Director | 72 | ["Current or Prior CEO","Operations / Manufacturing","Consumer Products","Mergers & Acquisitions / Integrations","Human Capital","Sustainability / Environmental","Finance / Accounting","ERM / Risk Management","International / Emerging Markets","Other Public Board Experience","More than four decades of global leadership experience in the agribusiness, food, and investment sectors","Chairman and Chief Executive Officer of Continental Grain Company since 1997","Oversaw Conti’s transformation into a diversified global investment firm","Serves on the boards of Loews Corp. since 1997 and Estée Lauder Companies Inc. since 2006","Board chair of Continental Grain Company since 1976","Board member of Syngenta Group Co. Ltd. since 2018","Board member of Wayne-Sanderson Farms LLC since 2011","Bachelor of Arts degree, magna cum laude, from Amherst College","Completed the Advanced Management Program at Harvard Business School"] | ["Audit"] | 2026 |
| Richard Mulligan | Mallinckrodt Professor of Genetics, Emeritus; Director | 71 | ["Current or Prior CEO","Mergers & Acquisitions / Integrations","Human Capital","Sustainability / Environmental","Finance / Accounting","ERM / Risk Management","International / Emerging Markets","Other Public Board Experience","Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School","Visiting Scientist at the Koch Institute for Integrative Cancer Research at MIT","Portfolio Manager at Icahn Capital","Founding Partner and Senior Managing Director of Sarissa Capital Management LP","Mallinckrodt Professor of Genetics at Harvard and Director of the Harvard Gene Therapy Initiative","Professor of Molecular Biology at MIT","Member of the Whitehead Institute for Biomedical Research","Board member of Sana Biotechnology, Inc. since 2018","Board member of Bausch Health Companies Inc. since 2022","Director of Biogen Inc. from 2009 to 2023","Director of Enzon Pharmaceuticals from 2011 to 2013","Director of Cellectis SA from 2007 to 2013","PhD in Biochemistry from Stanford University School of Medicine","B.S. in Biology from MIT","World-class scientific expertise and a track record of innovation"] | ["Governance & Corporate Responsibility"] | 2026 |
| Virginia C. Drosos | Former Chief Executive Officer and Director | 63 | ["Current or Prior CEO","Operations / Manufacturing","Consumer Products","Innovation / R&D","Mergers & Acquisitions / Integrations","Human Capital","Sustainability / Environmental","Finance / Accounting","ERM / Risk Management","International / Emerging Markets","Technology / IT","Other Public Board Experience","Chief Executive Officer of Signet Jewelers Ltd.","Chief Executive Officer of Assurex Health, Inc.","25 years at The Procter & Gamble Company, including Group President Global Beauty","extensive relevant experience","deep consumer insights","proven ability to drive innovation"] | ["Audit","Human Capital & Compensation","Governance & Corporate Responsibility"] | 2026 |
